Pancreatic | Interview with E Gabriela Chiorean, MD

1:05:24
 
Share
 

Manage episode 229273557 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Pancreatic Cancer Update – Part 2: Our interview with Dr Chiorean highlights the following topics as well as cases from her practice:

  • Biomarker-driven and molecular-targeted therapies for patients with adenocarcinoma of the pancreas: 0m0s
  • Rationale for the investigation of PEGPH20 in combination with pembrolizumab for previously treated hyaluronic acid (HA)-high metastatic pancreatic cancer: 4m40s
  • Tolerability and quality of life with PEGPH20 in combination with chemotherapy; mitigation of associated thromboembolic events: 6m59s
  • Ongoing Phase II trial of PEGPH20 with pembrolizumab for previously treated HA-high metastatic pancreatic ductal adenocarcinoma: 10m14s
  • Testing for emerging biomarkers (eg, microsatellite instability) of response to immune checkpoint inhibitors in metastatic pancreatic cancer: 11m49s
  • Incidence of germline BRCA mutations and response to PARP inhibition: 15m27s
  • Case: A 55-year-old woman presents with back pain and dyspepsia and is diagnosed with borderline resectable adenocarcinoma of the pancreas: 17m55s
  • Risk of relapse with and without adjuvant chemotherapy for patients with lymph node involvement: 24m45s
  • Clinical experience with adjuvant FOLFIRINOX and gemcitabine/nab paclitaxel: 29m46s
  • Activity, tolerability and dosing of adjuvant FOLFIRINOX: 31m39s
  • Role of neoadjuvant chemotherapy in the treatment of resectable or borderline resectable adenocarcinoma of the pancreas: 33m55s
  • Case: A 69-year-old woman with metastatic pancreatic cancer receives nal-IRI/5-FU/LV after experiencing disease progression on gemcitabine/nab paclitaxel: 38m26s
  • Response and tolerability with FOLFIRINOX compared to gemcitabine/nab paclitaxel: 41m49s
  • Second-line therapy options for metastatic pancreatic cancer: 46m59s
  • SWOG-S1513: An ongoing Phase II trial evaluating FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as second-line therapy for metastatic pancreatic cancer: 50m42s
  • Investigation of CDK4/6 inhibition-based therapies for advanced pancreatic cancer: 52m21s
  • Second opinion: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 54m34s
  • Importance of palliative care in managing the symptoms of pancreatic cancer: 1h1m22s

Select publications

2183 episodes